Karen Lewis - Jun 1, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief People Officer
Signature
/s/ David Watson, attorney-in-fact for Karen Lewis
Stock symbol
APLS
Transactions as of
Jun 1, 2023
Transactions value $
-$259,450
Form type
4
Date filed
6/2/2023, 04:40 PM
Previous filing
Apr 5, 2023
Next filing
Jan 17, 2024

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -5K -4.5% $0.00 106K Jun 1, 2023 Common Stock 5K $34.11 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from an established 10b5-1 plan.
F2 This includes 74 shares from the 4/30/23 ESPP Purchase.
F3 This stock option was granted on 5/4/2020 and has a four year vesting period. 25% vest one year from grant date. The remaining 75% vest monthly over the last three years of the four year vesting period.